This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)

Tipranks - Tipranks - Fri Jun 19, 7:42AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL) with bullish sentiments.

Claim 55% Off TipRanks

Zymeworks (ZYME)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Zymeworks. The company’s shares closed last Wednesday at $23.14.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.8% and a 47.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zymeworks with a $38.71 average price target, which is a 71.1% upside from current levels. In a report issued on June 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $46.00 price target.

See the top stocks recommended by analysts >>

Amylyx Pharmaceuticals Inc (AMLX)

Goldman Sachs analyst Corinne Johnson maintained a Buy rating on Amylyx Pharmaceuticals Inc today and set a price target of $23.00. The company’s shares closed last Wednesday at $15.25.

According to TipRanks.com, Johnson is a 4-star analyst with an average return of 8.6% and a 55.6% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, Syndax Pharmaceuticals, and Oric Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $24.86 average price target, implying a 64.4% upside from current levels. In a report issued on June 16, H.C. Wainwright also maintained a Buy rating on the stock with a $34.00 price target.

AbCellera Biologics (ABCL)

BMO Capital analyst Evan Seigerman maintained a Buy rating on AbCellera Biologics yesterday and set a price target of $7.00. The company’s shares closed last Wednesday at $5.44.

According to TipRanks.com, Seigerman is a 4-star analyst with an average return of 7.0% and a 52.4% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and ACADIA Pharmaceuticals. ;'>

Currently, the analyst consensus on AbCellera Biologics is a Strong Buy with an average price target of $9.40.

Read More on ZYME:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).